Highlights Gan & Lee Pharmaceuticals.

Equities

603087

CNE100003ZH1

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 16/04/2026			5-day change	1st Jan Change
65.97 ^CNY	+0.02%		+3.61%	-3.09%

04-16	Gan & Lee Pharmaceuticals Gets Nod to Trial GLR1062 Injection	MT
04-15	Gan & Lee Pharmaceuticals' Subsidiary Doses First Subject for Phase III of GZR33 Injection Trial; Shares Up 3%	MT

Highlights

04-16	Gan & Lee Pharmaceuticals Gets Nod to Trial GLR1062 Injection	MT
04-09	Gan & Lee Pharmaceuticals - signs exclusive license agreement with JW Pharmaceutical	RE
04-09	Gan & Lee Pharmaceuticals and Jw Pharmaceutical Sign Exclusive License Agreement for Bofanglutide Injection in South Korea	CI
04-08	Gan & Lee Pharmaceuticals Gets Regulatory Approval for Diabetes Combo Drug	MT
03-31	Gan & Lee Pharmaceuticals Announces Once-Weekly Basal Insulin GZR4 Injection Meets Primary Endpoints In Two Pivotal Phase 3 Clinical Trials	CI
03-25	Gan & Lee Pharmaceuticals Gets Drug Trial Approval to Treat Obesity-Related Sleep Apnea	MT
03-03	Gan & Lee Pharmaceuticals Gets Regulatory Nod for Prostate Cancer Drug Trials	MT
01-22	Gan & Lee Pharmaceuticals Expects 2025 Profit to Jump Up to 95%	MT
01-15	Gan & Lee Pharmaceuticals Gets EU Approval for Insulin Injection; Shares Up 4%	MT
12-29	Lupin Limited Enters into License, Supply and Distribution Agreement with Gan & Lee Pharmaceuticals for Novel GLP-1 Receptor Agonist, Bofanglutide	CI
12-09	Gan & Lee Pharmaceuticals Gets Clinical Trial Approval For Atopic Dermatitis Drug	MT
11-18	Gan & Lee Pharmaceuticals Europe GmbH Announces Committee for Medicinal Products for Human Use of the European Medicines Agency Recommends the Approval of Insulin Glargine Injection	CI
30/10/25	Gan & Lee Pharmaceuticals. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
29/09/25	Gan & Lee Pharmaceuticals Signs National "Technology Transfer and Supply Agreement" in Brazil to Accelerate Local Insulin Manufacturing	CI
07/09/25	Tranche Update on Gan & Lee Pharmaceuticals.'s Equity Buyback Plan announced on September 6, 2024.	CI
02/09/25	Gan & Lee Pharmaceuticals.'s Equity Buyback announced on September 6, 2024, has expired with 3,540,021 shares, representing 0.6% for CNY 150.07 million	CI
08/08/25	Gan & Lee Pharmaceuticals' lH1 Profit Jumps 103%, Revenue Rises 57%	MT
07/08/25	Gan & Lee Pharmaceuticals. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
07/08/25	Gan & Lee Pharmaceuticals' H1 net profit up 102.0% Y/Y	RE
09/07/25	Gan & Lee Pharmaceuticals sees H1 net profit up 100.7-114.1% Y/Y	RE
08/07/25	Gan & Lee Pharmaceuticals' Insulin Aspart Receives Approval in Argentina	CI
21/06/25	Gan & Lee Pharmaceuticals Presents Multiple Results in Novel Diabetes Therapies At the American Diabetes Association's 85Th Scientific Sessions	CI
25/04/25	Gan & Lee Pharmaceuticals' 2024 Profit Jumps 81%, Operating Income Rises 17%; Shares Jump 10%	MT
25/04/25	Gan & Lee Pharmaceuticals' Q1 Profit Surged 225%, Operating Income Jumps 76%; Shares Jump 10%	MT
24/04/25	Gan & Lee Pharmaceuticals. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI